What question did this study set out to answer?

This study evaluates the risk of iron toxicity among hemodialysis patients undergoing intravenous iron treatment.

March 25, 2026Medical SciencesOpen Access

Analysis of Potential Iron Toxicity in Hemodialysis Patients Under Intravenous Iron Treatment

View Full Paper

Ask AI

Bookmark

Authors

Analysis finds no increase in iron toxicity parameters among hemodialysis patients on iron therapy, despite higher iron stores.

This study evaluates the risk of iron toxicity among hemodialysis patients undergoing intravenous iron treatment.
Conducted magnetic resonance imaging to assess hepatic iron deposition in 56 hemodialysis patients.
Related hepatic iron levels to clinical parameters and analyzed plasma protein oxidative stress.
Measured iron and cytokine levels in peripheral blood mononuclear cells (PBMCs).
Patients with higher hepatic iron deposition had longer hemodialysis durations (42.0 months vs. 4.9 months, p < 0.001).
Those with higher hepatic iron deposition also had elevated ferritin levels (1200 ng/mL vs. 429 ng/mL, p < 0.001).
No differences were observed in transferrin saturation or hepatic enzyme serum concentrations between groups.
A decrease in IL-6 levels was noted in patients with higher hepatic iron deposition.

Peña-Esparragoza et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark